New remedy for diabetes demonstrates good results in weight loss
Science Translational Medicine in the October 30 edition. The results still indicate a high potential for reversal of the metabolic syndrome
The mechanism of action of the new medication unites the effects of two hormones: GLP-1 and GIP. These two hormones, called incretin hormones, are released naturally in the intestine when we feed, and act on the pancreas stimulating insulin secretion, which will reduce blood glucose levels. There are already in the market injectable medications for type 2 diabetes with the effect of the hormone GLP-1, and that despite leading to weight loss, have side effects such as nausea or vomiting. However, there are no commercially available drugs that have the effects of GIP, and through scientific studies it is known that this hormone controls sugar levels, but does not lead to weight gain.
The advantage of the new medication, called of unimolecular incretinic double agonist (
unimolecular dual incretin co-agonist ) is to stimulate insulin production and reduce the production of glucagon, which is a hormone that increases glucose. Another effect is also to slow the emptying of the stomach after the meal, prolonging the sensation of satiety and, therefore, reducing the hunger. By having GIP hormone action, the new remedy improves the feeling of nausea. The results still indicate a high potential for reversal of the metabolic syndrome, which is when the diabetic presents obesity, high levels of cholesterol or triglycerides and associated high blood pressure. The results on weight loss in rats guinea pigs who made use of the new remedy are promising. A comparison was made between the two drugs: the first with GLP-1 action alone and the second, the new double-acting drug. In rats that received only the one with GLP-1 action there was loss of 15.4% of body weight, prevention of fat accumulation and reduction of food intake. In those who received the new drug, there was a 20.8% reduction in body weight, greater than the effect of GLP-1 alone.
Certainly, the dissemination of such promising results is excellent news. Diabetes is a disease with a great potential to cause complications such as blindness, kidney failure, myocardial infarction and amputations. The study of new medicines is essential to broaden the horizons of treatment, and all we need (and want to) hear is good news!
To mark the National Day to Combat Cancer , November 27, the National Cancer Institute (INCA) has released new numbers of the disease in the country. Named Cancer Surveillance Information , the study had information from 22 Population Base Cancer Registries (RCBP) and another 11 RCBPs covering the period between 1987 and 2009.
Experts from Rio de Janeiro started a research to investigate whether the Zika virus can cause neurological problems in adults as well. The relationship between this virus and neurological diseases in infants, such as microcephaly and arthrogryposis, has been accepted. However, last week was reported the genetic sequencing of the Zika virus and the experts realized a genetic proximity to the Japanese encephalitis virus.